Cybin is trading at $11.57, up +5.72%, with the move best explained by biotech-sector strength.
- Biotech ETF XBI is up 2.10%, while sector sentiment is supported by M&A activity and positive clinical-trial news.
- No clear company-specific announcement explaining the gain was identified.
- Helus Pharma’s investor presentation was scheduled for October 21 at 9:00 a.m. EDT; available information does not establish it as the cause of the move.